Saturday, 30 May 2020


Tricida readies IPO

06 June 2018 | News

The company says its goal is to slow the progression of chronic kidney disease (CKD) via the treatment of metabolic acidosis (MA).

Singapore-  South San Francisco, CA-based Tricida (TCDA) has filed a preliminary prospectus for a $150M IPO.

The company says its goal is to slow the progression of chronic kidney disease (CKD) via the treatment of metabolic acidosis (MA). Lead candidate is Phase 3-stage TRC101, a non-absorbed polymer designed to treated MA by binding to and removing acid from the GI tract. A U.S. marketing application is on tap for H2 2019.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account